The DISCOVERY PENTA study: a DIrect Statin COmparison of LDL‐C Value – an Evaluation of Rosuvastatin therapY compared with atorvastatin

References

• Castelli WP. Epidemiology of coronary heart disease: the Framingham study. Am J Med 1984;76:4–12
   PubMed Web of Science ®Google Scholar
• Wilson PW, Anderson KM, Castelli WP. Twelve-year incidence of coronary heart disease in middle-aged adults during the era of hypertensive therapy: the Framingham offspring study. Am J Med 1991;90:11–6
   Google Scholar
• Assmann G, Schulte H, Cullen P. New and classical risk factors – the Munster heart study (PROCAM). Eur J Med Res 1997;2:237–42
   Google Scholar
• Anon. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994;344:1383–9
   PubMed Web of Science ®Google Scholar
• Shepherd J, Cobbe SM, Ford I, et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia [West of Scotland Coronary Prevention Study Group]. New Engl J Med 1995;333:1301–7
   PubMed Web of Science ®Google Scholar
• Sacks FM, Pfeffer MA, Moye LA, et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels [Cholesterol and Recurrent Events Trial investigators]. New Engl J Med 1996;335:1001–9
   PubMed Web of Science ®Google Scholar
• Downs JR, Clearfield M, Weis S, et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS (Air Force/Texas Coronary Atheroclerosis Prevention Study). J Am Med Assoc 1998;279:1615–22
   PubMed Web of Science ®Google Scholar
• The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. New Engl J Med 1998;339:1349–57
   Google Scholar
• Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20 536 high-risk individuals: a randomised placebo-controlled trial. Lancet 2002;360:7–22
   PubMed Web of Science ®Google Scholar
• Sever PS, Dahlof B, Poulter NR, et al. [ASCOT investigators]. Prevention of coronary and stroke events with atorvastatin in hyper tensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial – Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. Lancet 2003;361: 1149–58
   Google Scholar
• Colhoun HM, Betteridge DJ, Durrington PN, et al. [CARDS investigators]. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial. Lancet 2004;364: 685–96
   Google Scholar
• Pearson TA, Laurora I, Chu H, Kafonek S. The lipid treatment assessment project (L-TAP): a multicenter survey to evaluate the percentages of dyslipidemic patients receiving lipid-lowering therapy and achieving low-density lipoprotein cholesterol goals. Arch Intern Med 2000;160:459–67
   PubMed Web of Science ®Google Scholar
• EUROASPIRE II Study Group. Lifestyle and risk factor management and use of drug therapies in coronary patients from 15 countries; principal results from EUROASPIRE II Euro Heart Survey Programme. Eur Heart J 2001;22:554–72
   PubMed Web of Science ®Google Scholar
• Adult Treatment Panel III. Executive summary of the third report of the National Cholesterol Education Program (NCEP) Expert Panel on detection, evaluation, and treatment of high blood cholesterol in adults. J Am Med Assoc 2001;285:2486–97
   PubMed Web of Science ®Google Scholar
• De Backer G, Ambrosioni E, Borch-Johnsen K, et al., European Society of Cardiology Committee for Practice Guidelines. European guidelines on cardiovascular disease prevention in clinical practice: third joint task force of European and other societies on cardiovascular disease prevention in clinical practice (constituted by representatives of eight societies and by invited experts). Eur J Cardiovasc Prev Rehabil 2003;10\(Suppl 1):S2–S78
   Google Scholar
• Athyros VG, Papageorgiou AA, Mercouris BR, et al. Treatment with atorvastatin to the National Cholesterol Educational Program goal versus ‘usual’ care in secondary coronary heart disease prevention [The GREek Atorvastatin and Coronary-heart-disease Evaluation (GREACE) Study]. Curr Med Res Opin 2002;18:220–8
   PubMed Web of Science ®Google Scholar
• Koren MJ, Hunninghake DB [ALLIANCE investigators]. Clinical outcomes in managed-care patients with coronary heart disease treated aggressively in lipid-lowering disease management clinics: the alliance study. J Am Coll Cardiol 2004;44:1772–9
   Google Scholar
• Jones PH, Davidson MH, Stein EA, et al. Comparison of the efficacy and safety of rosuvastatin versus atorvastatin, simvastatin, and pravastatin across doses (STELLAR* Trial). Am J Cardiol 2003;92:152–60
   PubMed Web of Science ®Google Scholar
• McKenney JM, Jones PH, Adamczyk MA, Cain VA, Bryzinski BS, Blasetto JW [STELLAR Study Group]. Comparison of the efficacy of rosuvastatin versus atorvastatin, simvastatin, and pravastatin in achieving lipid goals: results from the STELLAR trial. Curr Med Res Opin 2003;19:689–98
   Google Scholar
• Schuster H, Barter PJ, Stender S, et al. [Effective Reductions in Cholesterol Using Rosuvastatin Therapy I Study Group]. Effects of switching statins on achievement of lipid goals: Measuring Effective Reductions in Cholesterol Using Rosuvastatin Therapy (MERCURY I) study. Am Heart J 2004;147:705–13
   Google Scholar
• Shepherd J, Hunninghake DB, Stein EA, et al. Safety of rosuvastatin. Am J Cardiol 2004;94:882–8
   PubMed Web of Science ®Google Scholar
• Friedewald WT, Levy RI, Fredrickson DS. Estimation of the con centration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 1972;18:499–502
   Google Scholar
• Second Joint Task Force of European and other Societies. Prevention of coronary heart disease in clinical practice: recommendations of the Second Joint Task Force of European and other Societies on Coronary Prevention. Eur Heart J 1998;19:1434–503
   PubMedGoogle Scholar
• Strandberg TE, Feely J, Sigurdsson EL [DISCOVERY study group]. Twelve-week, multicenter, randomized, open-label comparison of the effects of rosuvastatin 10 mg/d and atorvastatin 10 mg/d in high-risk adults: a DISCOVERY study. Clin Ther 2004;26: 1821–33
   Google Scholar
• Middleton A, Fuat A, Strang C [UK DISCOVERY investigators]. Treating patients to lipid targets: first results of the DISCOVERY study. Poster presented at the PCCS Annual Meeting and AGM, 3–4 October 2003, Dublin, Eire. Available from http://www.pccs.org.uk [accessed 14 March 2005]
   Google Scholar
• Bots AFE. DISCOVERY, een vergelijkend onderzoek tusse vier HMG-CoA-reducataseremmers in de Nederlandse huisartsenpraktijk. Tijdschr Huisartsgeneesk 2004;21:29–35
   Google Scholar
• Kendrach MG, Kelly-Freeman M. Approximate equivalent rosuvastatin doses for temporary statin interchange programs. Ann Pharmacother 2004;38:1286–92
   PubMed Web of Science ®Google Scholar
• Cannon CP, Braunwald E, Rader DJ, et al. [Pravastatin or Atorvastatin Evaluation and Infection Therapy – Thrombolysis in Myocardial Infarction 22 Investigators]. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. New Engl J Med 2004;350:1495–504
   Google Scholar
• LaRosa JC, Grundy SM, Waters DD, et al. [Treating to New Targets (TNT) Investigators]. Intensive lipid lowering with atorvastatin in patients with stable coronary disease. New Engl J Med 2005;352:1425–35
   Google Scholar
• Nissen SE, Tuzcu EM, Schoenhagen P, et al. [REVERSAL Investigators]. Effect of intensive compared with moderate lipid-lowering therapy on progression of coronary atherosclerosis: a randomized controlled trial. J Am Med Assoc 2004;291:1071–80
   Google Scholar
• Grundy SM, Cleeman JI, Merz CN, et al. [National Heart, Lung, and Blood Institute; American College of Cardiology Foundation; American Heart Association]. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation 2004;110:227–39
   Google Scholar
• Foley KA, Simpson Jr RJ, Crouse 3rd JR, Weiss TW, Markson LE, Alexander CM. Effectiveness of statin titration on low-density lipoprotein cholesterol goal attainment in patients at high risk of atherogenic events. Am J Cardiol 2003;92:79–81
   Google Scholar
• McTaggart F, Buckett L, Davidson R, et al. Preclinical and clinical pharmacology of rosuvastatin, a new 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor. Am J Cardiol 2001;87:28B–32B
   Google Scholar
• Fellström B, Zannad F, Schmeider R, et al. A study to evaluate the Use of Rosuvastatin in subjects On Regular haemodialysis: an Assessment of survival and cardiovascular events – the AURORA study. Nephrol Dial Transplant 2003;18(Suppl) [abstract W520]
   Google Scholar
• Ridker PM [JUPITER Study Group]. Rosuvastatin in the primary prevention of cardiovascular disease among patients with low levels of low-density lipoprotein cholesterol and elevated high-sensitivity C-reactive protein. Rationale and design of the JUPITER trial. Circulation 2003;108:2292–7
   Google Scholar
• Kjekshus J, Eskilson C, Dunselman P, et al. COntrolled ROsuvastatin multiNAtional study in heart failure: design and rationale of the CORONA trial. Poster presented at the European Institute of Healthcare: A Deep Insight into Heart Failure. October 9, 2004
   Google Scholar
• Barter P, Taylor R, Ditmarsch M, Kallend D. Measuring Effective Reductions in Cholesterol Using Rosuvastatin therapY (MERCURY I): safety analysis from an open-label extension. Atherosclerosis 2005;6(Suppl) [abstract W16-P–005]
   Google Scholar
• Deedwania PC, Hunninghake DB, Bays HE, et al. Effects of rosuvastatin, atorvastatin, simvastatin, and pravastatin on atherpgenic dyslipidemia in patients with characteristics of the metabolic syndrome. Am J Cardiol 2005;95:360–6
   PubMed Web of Science ®Google Scholar
• Brewer Jr HB. Benefit-risk assessment of rosuvastatin 10 to 40 milligrams. Am J Cardiol 2003;92:23K–29K
   Google Scholar